

Diabetes and Abnormal Glucose Tolerance in Women With Previous Gestational Diabetes

MERCÈ ALBAREDA, MD, PHD
AGUEDA CABALLERO, MD
GEMMA BADELL, MD
SANDRA PIQUER

ANGELS ORTIZ, PHD
ALBERTO DE LEIVA, MD, PHD
ROSA CORCOY, MD, PHD

OBJECTIVE — In Spanish women with gestational diabetes mellitus (GDM), we aimed to study the progression to diabetes and abnormal glucose tolerance (AGT) and identify predictive factors.

RESEARCH DESIGN AND METHODS — In 696 women with GDM and 70 control women, glucose tolerance was evaluated postpartum and at 5-year intervals.

RESULTS — In the GDM group, the cumulative risk for diabetes and AGT was 13.8 and 42.4% after 11 years compared with 0 and 2.8% in control women, respectively ($P < 0.05$). Independent predictive factors for diabetes were previous hyperglycemia, four abnormal glucose values on the diagnostic oral glucose tolerance test (OGTT) or overt diabetes during pregnancy, 2-h blood glucose on the diagnostic OGTT ≥ 11.7 mmol/l, gestational age at diagnosis < 24 weeks, and prepregnancy BMI ≥ 26.4 kg/m². All of these factors (some with different cutoff points) in addition to fasting glycemia were predictors of AGT also. The risk was nonlinear. Four abnormal glucose values on the diagnostic OGTT or overt diabetes during pregnancy was the strongest predictive factor for diabetes (relative risk 3.92), and prepregnancy BMI was the predictive factor with the highest attributable fraction in the whole group (13.3%). When first postpartum OGTT data were included in the analysis, predictors changed, but the overall prediction was similar.

CONCLUSIONS — Spanish women with GDM have an increased risk of diabetes and AGT. Predictive factors display a nonlinear relationship. The strongest predictive factor for diabetes was four abnormal glucose values on the diagnostic OGTT or overt diabetes during pregnancy; the factor with the highest attributable fraction in the whole group was prepregnancy BMI.

Diabetes Care 26:1199–1205, 2003

Gestational diabetes mellitus (GDM) is present in 0.6–15% of pregnant women and implies an increased risk of later diabetes and impaired glucose tolerance (IGT) at mid- and long-term follow-up (1–9). Diabetes is usually type 2 (6,8,10–12), although type 1 diabetes is also possible (8,11,12). Multiple antepar-

tum and postpartum independent predictors of later abnormal glucose tolerance have been identified (2–9). Some of them are modifiable, and intervention could avoid or delay the progression to AGT. In addition, autoantibodies could identify the subgroup of women at risk for type 1 diabetes (8,11,13).

From the Department of Endocrinology, Hospital de Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.

Address correspondence and reprint requests to Dr. Rosa Corcoy, Servei d'Endocrinologia, Hospital de Sant Pau, Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain. E-mail: rcorcoy@hsp.santpau.es.

Received for publication 8 July 2002 and accepted in revised form 3 January 2003.

Abbreviations: AGT, abnormal glucose tolerance; AFe, group attributable fraction; AFp, population attributable fraction; AUC, area under the curve; BG, blood glucose; GDM, gestational diabetes mellitus; IA2, tyrosine phosphatase; ICA, islet cell antibody; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; OR, odds ratio; RR, relative risk; WHO, World Health Organization.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

In this study, our objective was to assess the progression to diabetes and abnormal glucose tolerance (AGT) of Spanish women with GDM who attended our hospital and to identify predictive factors.

RESEARCH DESIGN AND METHODS

Patients and protocol

Of the 982 women diagnosed with GDM between 1986 and 1993 who attended the Diabetes and Pregnancy Clinic at the Hospital de Sant Pau de Barcelona, 696 returned postpartum for metabolic testing. Screening for GDM with the 50-g, 1-h glucose challenge test was scheduled in all pregnant women in the first visit, and women not diagnosed with GDM repeated the challenge at 24–28 and 31–34 weeks. Criteria for screening and glucose tolerance testing were those enunciated by the Second and Third Workshop-Conferences on Gestational Diabetes (14,15). The treatment protocol for women found to have GDM has been previously described (16).

A subset of 500 women who delivered in the center from January 1987 to December 1993 and had a normal screening test or oral glucose tolerance test (OGTT) in the third screening period were invited to participate as control subjects; 70 of them accepted.

In women with GDM, a 75-g OGTT was performed 6 weeks after delivery or upon cessation of breast-feeding, whichever occurred last. The second test was scheduled 5 years after the first one. No other regular assessment of diabetes was done, but in patients presenting with overt diabetes (17), the event was entered into the study at the moment it occurred. When a woman had GDM in subsequent pregnancies, only the first pregnancy was included in the analysis and the postpartum OGTTs of subsequent pregnancies were considered as part of the follow-up of the first one. Control women initiated follow-up 5 years after delivery. Results were evaluated according to World

Health Organization (WHO) 1998 criteria (18). When OGTT was diagnostic of diabetes, an additional test was scheduled to confirm the diagnosis, but the first one was used for the calculation of cumulative incidence. We analyzed the progression to diabetes and AGT (diabetes, IGT, impaired fasting glucose [IFG]) and the predictors of progression. Clinical criteria were used to differentiate between type 1 and type 2 diabetes, and C-peptide/insulin measurements were used for confirmation (17).

Antepartum variables considered as potentially predictive were family history of diabetes and previous hyperglycemia—GDM, IGT, or nondiagnostic hyperglycemia (fasting plasma glucose ≥ 110 mg/dl and < 140 mg/dl, in accordance with WHO 1985 criteria applicable at the time the patients attended [17])—age, prepregnancy BMI, previous pregnancies, history of poor obstetric outcome, diagnosis of GDM (gestational age, blood glucose [BG] values, area under the curve [AUC], number of abnormal glucose values, or overt diabetes during pregnancy), GHb, and autoantibody positivity after diagnosis (islet cell antibodies [ICAs], GAD, and tyrosine phosphatase [IA2] antibodies), requirement of insulin therapy, macrosomia (birth weight $\geq 4,000$ g), and spontaneous preterm delivery (< 37 weeks). Analyzed postpartum variables included additional pregnancies, additional diagnosis of GDM, BMI, and BMI increment at follow-up. In a subsequent analysis, first postpartum OGTT data (BG and AUC) were also included.

Laboratory analysis

A glucose oxidase method (Technicon RA-Xt Analyzer; Technicon Instruments, Tarrytown, NY) was used to measure plasma glucose concentration. GHb was measured by high-performance liquid chromatography, and because three different methods were used during the study period, results are expressed as SDs around the mean. ICAs were measured by indirect immunofluorescence after incubating patient sera for 18 h on frozen sections of human pancreas (blood type O) with aprotinin. The cutoff point for positivity was established at ≥ 5 JDF units. GAD and IA2 antibodies were measured by a radioligand immunoassay using ^{35}S -labeled in vitro-translated recombinant antigen. The threshold for positivity was




Figure 1—Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Cumulative incidence of diabetes in women with previous GDM is depicted according to the quintile of prepregnancy BMI (A) and after grouping the first four quintiles (B).

set at ≥ 4.2 units for GAD and ≥ 3.1 units for IA2 antibodies (95th centile of control samples).

Statistical analysis

Statistical analysis was performed with SPSS 10.0 software. Logistic regression analysis was used to compare women who did and did not attend the follow-up examination. Life table analysis was used to calculate the cumulative incidence of diabetes and AGT in women with GDM and control women, and differences between groups were assessed after a log-rank test. A Cox multiple hazard regression analysis was used to examine the relation between potentially predictive variables and the development of diabetes and AGT at follow-up. In continuous variables, the homogeneity of risk was evaluated assessing the risk for each quintile. The only exception was the number

of abnormal values in the diagnostic OGTT, which was divided into tertiles. As the risk for diabetes and AGT was not homogeneous throughout tertiles/quintiles, we grouped them according to the visual display of risk (Fig. 1). Multivariate analysis was used to identify independent variables that were significant predictors of diabetes or AGT. Four multivariate analyses were performed, excluding in each step variables with missing values as follows:

- Model 1: All potentially predictive variables included after transforming continuous variables into tertiles and quintiles and further regrouping, as previously described (343 patients)
- Model 2: Model 1, with exclusion of autoantibody positivity (443 patients)
- Model 3: Model 2, with exclusion of GHb (541 patients)




Figure 2—Cumulative incidence of diabetes and AGT (diabetes, IGT, IFG) in women with previous GDM (A) and control women (B) as determined by life table analysis. The cumulative rates of diabetes and overall AGT were 13.8 and 42.4% at 11 years of follow-up in women with GDM vs. 0 and 2.8% in control women.

- Model 4: Model 3, with exclusion of BMI and its increment at follow-up (660 patients)

Significance was set at $P = 0.012$ (Bonferroni correction for model 4 analysis). Statistical power was calculated assuming a unilateral α of 0.05 and different survival times for the control and study groups, with most analyses yielding powers $>70\%$.

Finally, we assessed the population attributable fraction (AFp; the proportion of excess cases resulting from an exposure in a defined population) and the exposed group attributable fraction (AFe; the equivalent proportion in the exposed group) (19). These were calculated as

$$AFe = (RR - 1)/RR$$

$$AFp = AFe \times \% \text{ women with the predictor}$$

where RR is relative risk.

RESULTS

Validity of the cohorts

Women with prior GDM. A logistic regression analysis, with attendance at follow-up as the dependent variable and all potential predictors of AGT as indepen-

dent ones, identified women with GDM who came for follow-up as more likely to have received insulin during pregnancy (odds ratio [OR] 1.75, 95% CI 1.17–2.58) and less likely to have had a macrosomic baby (OR 0.44, CI 0.2–0.97).

Control group. In a logistic regression analysis, with participation in the study as the dependent variable and BG response to 50-g challenge test at 31–34 weeks, maternal age at pregnancy, and newborn macrosomia as independent ones, control women participating in the follow-up study were more likely to have had a higher BG in response to 50-g challenge test (OR 1.4, CI 1.14–1.70).

Cumulative incidence of diabetes and AGT

At 6.16 years (0.05–13.73) of follow-up, 44 women had developed diabetes and 130 had developed AGT (44 diabetes, 61 IGT, and 25 IFG). At 11 years of follow-up, the cumulative risk for diabetes was 13.8% in women with prior GDM and 0% in control women ($P = 0.02$), whereas the corresponding rates for AGT were 42.4 and 2.8% ($P < 0.001$) (Fig. 2). Five women presented with type 1 diabetes,

which represented 11.4% of all diabetes cases.

Women with prior GDM and control women differed in the rate of GDM in pregnancies after the index pregnancy (65 vs. 0%), age at follow-up (37.5 [21.8–52.9] vs. 40 years [29.1–51.4]), length of follow-up (6.8 [0.1–13.7] vs. 9.6 years [3.5–13.3]), and follow-up OGTT (fasting BG 5 [3.7–13.9], 30-min BG 8.8 [4.4–19.4], 60-min BG 8.3 [3.3–24], 120-min BG 5.7 mmol/l [1.9–30.5], and AUC 22.3 [12.9–63.8] vs. 4.8 [3.8–6.0], 7.6 [4.2–11.5], 6.3 [2.8–12], 5 [2.3–8.5], and 18.5 mmol/l [10.7–29.1], respectively; $P < 0.001$). Rates of family history of diabetes (53.7 vs. 43.9%), subsequent pregnancies (15.1 vs. 20.9%), and BMI at follow-up (24.5 [16.2–40.3] vs. 24.8 [18.3–38.4] kg/m²) were similar.

Predictors of diabetes

For diabetes prediction, potentially predictive variables included in the multivariate analysis were previous hyperglycemia; family history of diabetes; history of poor obstetric outcome; pregestational BMI, 5th quintile (≥ 26.4 kg/m²) vs. 1st–4th quintiles; gestational age at diagnosis, 1st quintile (<24 weeks) vs. 2nd–5th quin-

Table 1—Clinical and analytical characteristics of women with prior GDM included as potentially predictive variables of AGT at 6.16 years (0.05–13.73) of follow-up

Potentially predictive variables	
Family history of diabetes (%)	373/695 (53.7)
Previous hyperglycemia (%)*	54/695 (7.8)
Age (years)	31 (17–44)
Prepregnancy BMI (kg/m ²)	23.3 (15.9–37.9)
One or more previous pregnancies (%)	446/694 (64.3)
History of poor obstetric outcome (%)†	93/694 (13.4)
Gestational age at diagnosis (weeks)	30 (8–39)
OGTT at diagnosis (mmol/l)	
Fasting blood glucose	4.9 (2.8–9)
60-min blood glucose	11.9 (7.7–18.6)
120-min blood glucose	10.3 (4.7–18.6)
180-min blood glucose	7.7 (1.8–14.6)
OGTT AUC	28.3 (23.6–47)
Number of abnormal values on OGTT (n)	2 (2–4)
GHb (SD)‡	−0.62 (−4.29 to 6.91)
Autoantibody positivity (%)	75/535 (14%: ICA 14%, GAD 1.5%, IA2 0.2%)
Insulin therapy (%)	472/695 (67.9)
Macrosomia (%)§	25/692 (3.6)
Spontaneous preterm delivery (%)	17/691 (2.5)
Subsequent pregnancies (%)	105/696 (15.1)
Subsequent diagnosis of GDM (%)	69/105 (65)
BMI at follow-up (kg/m ²)	24.5 (16.2–40.3)
BMI increment at follow-up (kg/m ²)	1.52 (−3.73 to 12.29)

Data are n (%) and median (range). *Previous hyperglycemia includes IGT, GDM, or nondiagnostic hyperglycemia, †poor obstetric outcomes are macrosomia, hypertension, recurrent miscarriages, unexplained fetal death, hydramnios, major congenital malformations, recurrent urinary infections, or pyelonephritis in previous pregnancies; ‡GHb was measured at a median gestational age of 33 weeks (11–42); §macrosomia: birthweight $\geq 4,000$ g.

tiles; fasting, 1-, 2-, and 3-h BG values (5th quintile vs. 1st–4th quintiles, with cutoff points at ≥ 5.5 , 13, 11.7, and 9.3 mmol/l, respectively); AUC, 5th quintile (≥ 30.6) vs. 1st–4th quintiles; number of abnormal values at GDM diagnosis, 3rd tertile (four abnormal values in the diagnostic OGTT or overt diabetes) vs. 2nd–3rd tertiles; GHb after diagnosis, 5th quintile (SD ≥ 0.42) vs. 1st–4th quintiles; autoantibody positivity; insulin treatment; macrosomia; preterm delivery; additional pregnancies and GDM; BMI at follow-up, 5th quintile (≥ 29.1 kg/m²) vs. 1st–4th quintiles; and BMI increment, 3rd–5th quintiles (≥ 0.98 kg/m²) vs. 1st–2nd quintiles.

Table 1 displays the values of predictive variables. We selected multivariate model 4 because it included 95% of women and had the highest prediction power (evaluated as the change in log likelihood from baseline). Independent predictors were previous hyperglycemia (RR 2.49, CI 1.22–5.07), four abnormal values in the diagnostic OGTT or overt

diabetes during pregnancy (RR 3.92, CI 1.86–8.28), 2-h BG in the diagnostic OGTT ≥ 11.7 mmol/l (RR 2.67, CI 1.35–5.28), gestational age at diagnosis < 24 weeks (RR 2.25, CI 1.21–4.18), and prepregnancy BMI ≥ 26.4 kg/m² (RR 3.02, CI 1.61–5.65) (P of the model < 0.001).

AFe of individual predictors was 59.9% for previous hyperglycemia, 74.5% for four abnormal values in the diagnostic OGTT or overt diabetes, 62.5% for 2 h-BG in the diagnostic OGTT ≥ 11.7 mmol/l, 55.5% for gestational age at diagnosis < 24 weeks, and 66.9% for prepregnancy BMI ≥ 26.4 kg/m². AFe was 4.2% for previous hyperglycemia, 4.1% for four abnormal values in the diagnostic OGTT or overt diabetes, 13.2% for 2 h-BG in the diagnostic OGTT ≥ 11.7 mmol/l, 10.9% for gestational age at diagnosis < 24 weeks, and 13.3% for prepregnancy BMI ≥ 26.4 kg/m². All five predictors account for 49.3% of the risk of diabetes in women with GDM.

The analysis was repeated including

glucose values and AUC of first postpartum OGTT among potentially predictive variables. Subjects and events were reduced because some women did not have this test, so that 351 women were included in the multivariate analysis; the 5th quintile of prepregnancy BMI (RR 4.64, CI 1.46–14.81) and the 5th quintile of postpartum 1-h OGTT BG (RR 5.94, CI 1.76–20.08) were the independent predictors ($P < 0.001$). AFe of all variables was 45.1%.

Risk of type 1 and type 2 diabetes

Independent predictors of type 1 diabetes were four abnormal values at diagnostic OGTT or overt diabetes, gestational age at diagnosis < 24 weeks, and AUC on the diagnostic OGTT ≥ 30.6 (data not shown). Independent predictors of type 2 diabetes were previous hyperglycemia, prepregnancy BMI ≥ 26.4 kg/m², four abnormal values at diagnostic OGTT or overt diabetes, and AUC on the diagnostic OGTT ≥ 30.6 (data not shown).

Predictors of AGT

For prediction of AGT and after analyzing the homogeneity of risk prediction in bivariate analysis, potentially predictive variables included in the multivariate analysis were those included for diabetes prediction, some of them with a different cutoff: pregestational BMI (4th–5th quintiles [≥ 24 kg/m²] vs. 1st–3rd quintiles), gestational age at diagnosis (1st–3rd quintiles [< 32 weeks] vs. 4th–5th quintiles), BMI at follow-up (4th–5th quintiles [≥ 25.5 kg/m²] vs. 1st–3rd quintiles), and BMI increment (3rd–5th quintiles [≥ 0.98 kg/m²] vs. 1st–2nd quintiles).

The multivariate model selected for AGT prediction was again model 4. Independent predictors were previous hyperglycemia (RR 1.94, CI 1.19–3.16), four abnormal values on the diagnostic OGTT or overt diabetes (RR 2.15, CI 1.9–3.87), fasting BG ≥ 5.5 mmol/l (RR 1.6, CI 1.02–2.51), 2-h BG ≥ 11.7 mmol/l (RR 2.05, CI 1.36–3.09), gestational age at diagnosis < 32 weeks (RR 1.93, CI 1.26–2.93), and prepregnancy BMI ≥ 24 kg/m² (RR 1.84, CI 1.26–2.68) (P of the model < 0.001).

AFe of independent predictors was 48.4% for previous hyperglycemia, 53.4% for four abnormal values on the diagnostic OGTT or overt diabetes, 37.6% for fasting BG ≥ 5.5 mmol/l, 51.3% for 2-h BG ≥ 11.7 mmol/l, 48.1%

for gestational age at diagnosis <32 weeks, and 45.7% for prepregnancy BMI ≥ 24 kg/m². AFp was 3.4% for previous hyperglycemia, 2.9% for four abnormal values on the diagnostic OGTT or overt diabetes, 8% for fasting BG ≥ 5.5 mmol/l, 10.8% for 2-h BG level ≥ 11.7 mmol/l, 27.5% for gestational age at diagnosis <32 weeks, and 18.1% for prepregnancy BMI ≥ 24 kg/m². Overall AFp was 55.7%.

Repeating the analysis including first postpartum OGTT, 285 women were included, with insulin therapy (RR 3.91, CI 1.17–13.06) and the 5th quintile of postpartum OGTT 2-h BG (RR 2.67, CI 1.22–5.83) being the independent predictors ($P = 0.003$). AFp of all variables was 63%.

CONCLUSIONS

Risk of diabetes and AGT

The study and control groups were reasonably representative of the original populations: women with GDM with follow-up differed from those without follow-up in the rate of macrosomia and insulin therapy (which, in turn, have not been found to be predictive of AGT or diabetes), and control women undergoing follow-up were slightly shifted toward “less normal” glucose tolerance (higher glycemic response to glucose screening during index pregnancy). We interpreted these findings as indicating that women with prior GDM who received insulin were probably more concerned about their risk of diabetes, but we have no explanation for the negative association with macrosomia. As to the reasons underlying the higher glycemic response to GDM screening in participating control women, we speculate that this could have been attributable to a higher rate of diabetic background in the family.

As expected, the cumulative incidence of diabetes and AGT in the women with previous GDM was higher than in control subjects (13.8 vs. 0% and 42.4 vs. 2.8%, respectively, 11 years after the incident pregnancy). In women of the same geographic area, ages 25–44 years, the prevalence of diabetes and IGT has been reported to be 1.7 and 8.3%, respectively (20), figures in the range of the cumulative incidence of AGT described here for the control group. Nevertheless, the progression rate of women with GDM to diabetes was lower than previously reported (2–5,8,9), but the risk of AGT was in the higher range. Because both IGT

and IFG imply a risk of future diabetes (18), we hypothesize that, with longer follow-up, the cumulative incidence of diabetes in these women might approach the rates seen in the literature. Given that the control group initiated follow-up 5 years after delivery, this might have shifted the survival curve to the right, spuriously increasing the difference between them and women with prior GDM. Nevertheless, a bias is impossible for the cumulative incidence of diabetes (0% in the control group) and probably minimal for AGT (2.8% in the control group).

In explanation for the differences between our study and other studies, it should be noted that we have a more comprehensive screening policy in our center: in addition to the usual screening at 24–28 weeks, additional tests are performed at the first visit and at 31–34 weeks. Patients diagnosed after a positive screening in the third period can be assumed to have a more subtle glucose metabolism derangement than those diagnosed earlier. This would mirror the situation described by O’Sullivan and Mahan (21), with the risk of progression to diabetes increasing as the criteria for GDM diagnosis become stricter. Ethnicity could be another reason, as most of our patients were Caucasian and the risk of diabetes is lower in these subjects (22). Finally, we speculate that tight targets of BG control during pregnancy (16) could have helped to preserve β -cell function (23).

Type of diabetes

As to the type of diabetes, these women, when becoming diabetic, essentially developed type 2 diabetes: the cumulative incidence of type 1 diabetes at 11 years was 0.7%, whereas published studies in Caucasian women with GDM have reported figures of 1.7–6.6% in follow-up periods of 2–11 years (8,11–13). This difference could be attributed to the fact that, with one exception (11), these other studies were performed in Northern Europe, where the risk of type 1 diabetes is higher than in Spain (24).

Predictors of diabetes and AGT

As expected, in accordance with previous reports (2,4,5,9), high prepregnancy BMI (surrogate of insulin resistance), severity of GDM (high BG values and early diagnosis), and previous hyperglycemia (both surrogates of inadequate β -cell function for the prevailing insulin resistance) were

independent predictors of AGT and diabetes at follow-up. It is important to note that the risk attributed to all quantitative predictors is nonlinear, a fact that has been described (only for some variables) in women with prior GDM (10) and in the general population (25). Moreover, it is important to note that prepregnancy BMI is a predictive factor of glucose tolerance at 26.4 kg/m² (slightly overweight range) in the case of diabetes and 24 kg/m² (normal weight range) in the case of AGT. Surprisingly, insulin therapy and BMI at follow-up were not among the predictors, probably because they were represented by other variables (severity of GDM for insulin therapy, and prepregnancy BMI for BMI at follow-up). Furthermore, additional pregnancies did not increase the risk of future diabetes, a fact that contrasts with the results of Peters et al. (26), who reported that a single pregnancy more than tripled the risk of type 2 diabetes in Hispanic women with previous GDM. This could be because of the higher risk of diabetes in the aforementioned study, meaning that the additional risk of subsequent pregnancies would become more evident. The fact that the Summary of the Fourth Workshop-Conference on Gestational Diabetes acknowledges that the influence of parity on the risk of diabetes is controversial and may vary among ethnic groups (27) highlights the importance of this negative finding.

Even more surprising in our study was the fact that autoantibody positivity was not a predictor of type 1 diabetes. Most study findings concur with this point (8,11–13). In 1996, our group published findings indicating that women with GDM who tested positive for ICAs had a higher prevalence of AGT early after delivery (28). At that time, our feeling was that these women would progress to diabetes (either typical type 1 or latent autoimmune diabetes of the adult [LADA]). However, with longer follow-up, the progression to diabetes and AGT of the antibody negative cohort has become more pronounced, thus diminishing the differences present shortly after delivery.

In relation to the prediction of future diabetes and AGT, some information about AFe and AFp of diabetes predictors has been reported for the general population (29), but is lacking for women with GDM. We would like to remark on its importance, especially on that of AFp, which indicates the percentage of risk in

the whole group that can be attributed to the risk factor, in contrast to AFe and RR, which only point out the risk in subjects positive for a specific predictor. In our study, four abnormal values on the diagnostic OGTT or overt diabetes had the highest AFe for both diabetes and AGT; therefore, it was the strongest predictor in the group of women who presented with this marker (AFe 74.5%). However, because of its low prevalence in the group (4.7%), it became a poor predictor for the whole group (AFp 4.1%). On the other hand, a prepregnancy BMI ≥ 26.4 kg/m² and a 2-h BG on the diagnostic OGTT ≥ 11.7 mmol/l were the best predictors for diabetes in the whole group (AFp 13%), and gestational age at diagnosis < 32 weeks was the best predictor for AGT (AFp 27.5%). The underlying reason is that even when these predictive factors do not have the highest RR, they are present in an important proportion of the population (20% for the first two—the highest quintile—and 60% for the last one—the first three quintiles). An additional merit of these predictive factors is that they are known in all women with GDM after diagnosis.

Finally, when the first postpartum OGTT data were included, the predictors differed, but overall prediction was similar (worse for diabetes and better for AGT). We favor the model not including first postpartum OGTT because it permits an earlier identification of women at risk.

In conclusion, Spanish women with GDM have an increased risk of diabetes and AGT. The predictive factors display a nonlinear relationship. The strongest predictive factor for diabetes was four abnormal glucose values on the diagnostic OGTT or overt diabetes during pregnancy, and the predictive factor with the highest AFp was prepregnancy BMI.

Acknowledgments—M.A. was the recipient of a Postgraduate Training Grant of Comissionat per a Universitats i Recerca, Generalitat de Catalunya.

The authors wish to acknowledge the contribution of Ignasi Gich to the statistical analysis.

References

1. King H: Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. *Diabetes Care* 21 (Suppl. 2):B9–B13, 1998

2. Henry OA, Beischer NA: Long-term implications of gestational diabetes for the mother. *Baillieres Clin Obstet Gynaecol* 5: 461–483, 1991
3. Metzger BE, Cho NH, Roston SM, Radvany R: Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. *Diabetes Care* 16:1598–1605, 1993
4. O'Sullivan JB: Gestational diabetes: factors influencing the rates of subsequent diabetes. In *Carbohydrate Metabolism in Pregnancy and the Newborn* 1978. Sutherland HW, Stowers JM, Eds. Berlin, Springer-Verlag, 1979, p. 425–435
5. Mestman JH: Follow-up studies in women with gestational diabetes mellitus: the experience at Los Angeles County/University of Southern California Medical Center. In *Gestational Diabetes*. Weiss PAM, Coustan DR, Eds. Vienna, Springer-Verlag, 1988, p. 191–198
6. Damm P, Kühl C, Bertelsen A, Molsted-Pedersen L: Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus. *Am J Obstet Gynecol* 167:607–616, 1992
7. Coustan DR, Carpenter MW, O'Sullivan PS, Carr SR: Gestational diabetes: predictors of subsequent disordered glucose metabolism. *Am J Obstet Gynecol* 168: 1139–1145, 1993
8. Füchtenbusch M, Ferber K, Standl E, Ziegler AG: Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening. *Diabetes* 46: 1459–1467, 1997
9. Herranz L, García-Ingelmo MT, Martín-Vaquero P, Grande C, Pallardo LF: Follow-up of women with gestational diabetes: incidence and factors associated with later development of abnormal glucose tolerance (Abstract). *Diabetologia* 41 (Suppl. 1): A125, 1998
10. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA: Predicting future diabetes in Latino women with gestational diabetes. *Diabetes* 44:586–591, 1995
11. Beischer NA, Wein P, Sheedy MT, Mackay IR, Rowley MJ, Zimmet P: Prevalence of antibodies to glutamic acid decarboxylase in women who have had gestational diabetes. *Am J Obstet Gynecol* 173:1563–1569, 1995
12. Petersen JS, Dyrberg T, Damm P, Kühl C, Molsted-Pedersen L, Buschard K: GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. *Diabetologia* 39:1329–1333, 1996
13. Damm P, Kühl C, Buschard K, Jakobsen BK, Svejgaard A, Sodayez-Goffaux F, Shattock M, Bottazzo GF, Molsted-Pedersen L: Prevalence and predictive value of islet cell antibodies and insulin autoantibodies in women with gestational diabetes. *Diabet Med* 11:558–563, 1994
14. American Diabetes Association: Second Workshop-Conference on Gestational Diabetes: summary and recommendations. *Diabetes Care* 34 (Suppl. 2):123–126, 1985
15. Metzger BE, the Organizing Committee: Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes* 40 (Suppl. 2):197–201, 1991
16. García-Patterson A, Corcoy R, Balsells M, Altirriba O, Adelantado JM, Cabero LL, de Leiva A: In pregnancies with gestational diabetes mellitus and intensive therapy, perinatal outcome is worse in small-for-gestational-age newborns. *Am J Obstet Gynecol* 179:481–485, 1998
17. World Health Organization: *Diabetes Mellitus: Report of a WHO Study Group*. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
18. Alberti KGM, Zimmet PZ for the WHO Consultation: Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15:539–553, 1998
19. Miettinen OS: Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am J Epidemiol* 99: 325–332, 1974
20. Castell C, Tresserras R, Serra J, Goday A, Lloveras G, Salleras L: Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. *Diabetes Res Clin Pract* 43:33–40, 1999
21. O'Sullivan JB, Mahan CM: Criteria for the oral glucose tolerance test in pregnancy. *Diabetes* 13:278–285, 1964
22. King H, Rewers M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. *Diabetes Care* 16:157–177, 1993
23. Buchanan TA: Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. *J Clin Endocrinol Metab* 86:989–993, 2001
24. Karvonen M, Tuomilehto J, Libman I, LaPorte R: A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 36:883–892, 1993
25. Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, Sellers TA, Lazovich D, Prineas RJ: Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. *Arch Intern Med* 160:2117–2128, 2000

26. Peters RK, Kjos SL, Xiang A, Buchanan TA: Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. *Lancet* 347: 227–230, 1996
27. Metzger BE, Coustan DR, the Organizing Committee: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care* 21 (Suppl. 2): B161–B167, 1998
28. Mauricio D, Balsells M, Morales J, Corcoy R, Puig-Domingo M, de Leiva A: Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus. *Diabetes Metab Rev* 12:275–285, 1996
29. Okosun IS: Racial differences in rates of type 2 diabetes in American women. How much is due to differences in overall adiposity? *Ethn Health* 6:27–34, 2001